Merck Serono to launch MS injection device RebiSlide

Merck Serono has announced the imminent European and Canadian launch of RebiSlide, its new injection device for multiple sclerosis patients.

The device is a multidose manual injection pen for the self-administration of Rebif – the company's relapsing multiple sclerosis therapy – and is able to contain a week's supply of the drug.

It has been approved in the EU, Canada and Australia and has already been launched in Hungary, with imminent launches in Italy, Greece and Canada representing the next phase of its international rollout.

The product joins a variety of other Rebif delivery devices in the company's portfolio, including RebiSmart, RebiDose and Rebiject II.

Belen Garijo, head of global operations at Merck Serono, said: "The introduction of RebiSlide … underscores our commitment to continuous advancement in multiple sclerosis treatments, by offering patients different administration options to suit their individual needs."

Earlier this month, the company announced a new collaboration with Dr Reddy's Laboratories in the field of biosimilar therapy development.